Aivar Linnamäe, MD

• CEO of the company
• Aivar has extensive pharma sector experience since 1992
• Aivar is the representative of the major shareholder Magnum Medical Group, the leading Baltic pharmaceuticals wholesaler and retailer
• He is also the co-founder of Magnum Medical and Magnum Group
   

Toomas Neuman, Ph.D.

• CSO of the company
• Toomas, an expert in molecular and cell biology, is the founder of several biotechnology companies in US and Estonia
• His team performed the first autologous stem cell therapy on a Parkinson's disease patient at the Cedars Sinai Medical Center (Los Angeles, CA) in 1998
• He was a founder of Neurogeneration, later Celmed Biosciences (Los Angeles, CA). Company raised $40 mln for development of cell therapy procedures
• In 2000 Toomas and his colleagues founded CeMines, Inc. to develop molecular diagnostic techniques for early detection and monitoring of cancer using proprietary Fingerprinting platform technology
• Toomas, being a Professor at the Tallinn University of Technology (Estonia) founded also several biotechnology companies including Protobios, FibroTx, Cellin Technologies and BiotaP in Estonia
• Toomas is the author of more than 70 scientific publications in international journals and has presented his work at numerous scientific meetings. He is inventor of 8 patents and 7 patent applications

Pieter Spee, Ph.D.

• CTO of the company
• Pieter has more than 10 years experience from line- and project management positions in pharmaceutical industry
• He has served as Scientific Director of Translational Immunology at Novo Nordisk A/S. His major contributions were related to development of fully human mAb 1-7F9 (now BMS-986015) currently in clinical development for treatment of Acute Myeloid Leukemia and Multiple Myeloma and development of humanized mAb humZ270 (NNC-0141-0100) currently in clinical development for treatment of Rheumatoid Arthritis
• Pieter has published 16 papers in scientific journals and is inventor of 8 patent applications